OTCM
RBSH
Market cap3kUSD
Jul 11, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Rebus Holdings Inc
Chart & Performance
Profile
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||
Revenues | ||||||||
Cost of revenue | 664 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (664) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | 233 | |||||||
Tax Rate | ||||||||
NOPAT | (897) | |||||||
Net income | (1,253) -177.59% | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 310 | |||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | 2,284 | |||||||
Net debt | 305 | |||||||
Cash flow | ||||||||
Cash from operating activities | (706) | |||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | (478) | |||||||
Balance | ||||||||
Cash | 5 | |||||||
Long term investments | ||||||||
Excess cash | 5 | |||||||
Stockholders' equity | (65,294) | |||||||
Invested Capital | 60,367 | |||||||
ROIC | ||||||||
ROCE | 13.48% | |||||||
EV | ||||||||
Common stock shares outstanding | 31,819 | |||||||
Price | 0.01 -71.80% | |||||||
Market cap | 239 -57.55% | |||||||
EV | 544 | |||||||
EBITDA | (610) | |||||||
EV/EBITDA | ||||||||
Interest | 69 | |||||||
Interest/NOPBT |